Published in Arch Neurol on September 01, 2012
Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. J Neurol (2013) 1.48
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol (2015) 1.26
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm (2015) 1.15
Demographic and clinical features of neuromyelitis optica: A review. Mult Scler (2015) 1.14
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07
Neuromyelitis optica and pregnancy. J Neurol (2013) 1.06
The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care (2013) 0.94
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol (2014) 0.94
Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci (2012) 0.92
Optic neuritis in neuromyelitis optica. Prog Retin Eye Res (2013) 0.90
Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci (2013) 0.89
A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iran J Neurol (2015) 0.89
Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One (2013) 0.89
Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm (2016) 0.86
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84
Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol (2015) 0.83
The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol (2014) 0.83
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation (2016) 0.80
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic. Curr Treat Options Neurol (2016) 0.79
Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. J Neuroinflammation (2015) 0.78
Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflamm (2014) 0.77
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI. AJNR Am J Neuroradiol (2016) 0.77
Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol (2014) 0.76
A Case Study of Intractable Vomiting with Final Diagnosis of Neuromyelitis Optica. Case Rep Pediatr (2015) 0.75
Inflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis Optica. Neuroophthalmology (2013) 0.75
Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clin Med Insights Case Rep (2014) 0.75
Multiple sclerosis: clinical features and MRI findings in Northern China. Eur J Med Res (2014) 0.75
3D-DIR for early differential diagnostic and prognostic evaluation of NMO. Exp Ther Med (2016) 0.75
Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. J Res Med Sci (2017) 0.75
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol (2016) 0.75
Clinical proteomics of enervated neurons. Clin Proteomics (2016) 0.75
Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci (2015) 0.75
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature (2004) 11.03
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc (2009) 2.32
Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain (2011) 2.21
Explicating an evidence-based, theoretically informed, mobile technology-based system to improve outcomes for people in recovery for alcohol dependence. Subst Use Misuse (2011) 1.84
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom (2012) 1.82
Ballistics for the neurosurgeon. Neurosurgery (2008) 1.75
Visceral leishmaniasis in a New York foxhound kennel. J Vet Intern Med (2002) 1.62
Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc (2007) 1.62
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Use of MR cell tracking to evaluate targeting of glial precursor cells to inflammatory tissue by exploiting the very late antigen-4 docking receptor. Radiology (2012) 1.51
Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation. Radiology (2012) 1.49
Human aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica. Arch Neurol (2012) 1.47
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol (2008) 1.46
Endoscopy by nonphysicians. Gastrointest Endosc (2009) 1.42
Integrated imaging approach with MEG and DTI to detect mild traumatic brain injury in military and civilian patients. J Neurotrauma (2009) 1.39
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation (2008) 1.32
The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem (2002) 1.31
Safe and effective intravenous thrombolysis for acute ischemic stroke caused by left atrial myxoma. J Stroke Cerebrovasc Dis (2009) 1.30
Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist (2009) 1.29
The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey. Aust N Z J Public Health (2007) 1.29
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27
An e-health solution for people with alcohol problems. Alcohol Res Health (2011) 1.23
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health (2010) 1.18
Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol (2010) 1.18
Clinical practice. Transverse myelitis. N Engl J Med (2010) 1.17
NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers (2006) 1.14
Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma. Clin Gastroenterol Hepatol (2011) 1.14
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol (2010) 1.13
Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve (2009) 1.13
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol (2010) 1.11
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (2009) 1.11
Neuromyelitis optica. Curr Opin Neurol (2007) 1.10
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol (2012) 1.09
Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord (2012) 1.08
Addressing Tobacco Through Organizational Change (ATTOC) in residential addiction treatment settings. Drug Alcohol Depend (2011) 1.07
Telemedicine versus telephone for remote emergency stroke consultations: a critically appraised topic. Neurologist (2009) 1.06
In vivo biodistribution and biological impact of injected carbon nanotubes using magnetic resonance techniques. Int J Nanomedicine (2011) 1.04
Aboriginal and non-Aboriginal health differentials in Australian prisoners. Aust N Z J Public Health (2007) 1.04
Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. J Neurol Sci (2011) 1.02
Randomized multi-site trial of the Job Seekers' Workshop in patients with substance use disorders. Drug Alcohol Depend (2011) 1.01
Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist (2007) 0.98
Subclinical elevations of thyroid-stimulating hormone and assisted reproductive technology outcomes. Fertil Steril (2011) 0.97
Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist (2009) 0.97
Mortality among prisoners: how accurate is the Australian National Death Index? Aust N Z J Public Health (2005) 0.97
Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmun (2011) 0.96
MEG source imaging method using fast L1 minimum-norm and its applications to signals with brain noise and human resting-state source amplitude images. Neuroimage (2013) 0.94
The role of endoscopy in the management of patients with diarrhea. Gastrointest Endosc (2010) 0.93
Clinical predictors of psychogenic nonepileptic seizures: a critically appraised topic. Neurologist (2008) 0.93
An automatic MEG low-frequency source imaging approach for detecting injuries in mild and moderate TBI patients with blast and non-blast causes. Neuroimage (2012) 0.93
Direct and consensual murine pupillary reflex metrics: establishing normative values. Auton Neurosci (2009) 0.93
Role of endoscopic ultrasound-guided fine-needle aspiration cytology, viscosity, and carcinoembryonic antigen in pancreatic cyst fluid. Endosc Ultrasound (2015) 0.92
Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol (2004) 0.92
Transverse myelitis. Neurol Clin (2013) 0.92
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2010) 0.91
Disrupted daytime activity and altered sleep-wake patterns may predict transition to mild cognitive impairment or dementia: a critically appraised topic. Neurologist (2012) 0.90
Sex behind the prison walls. Aust N Z J Public Health (2002) 0.90
The two faces of neuromyelitis optica. Neurology (2014) 0.89
Uhthoff's phenomena in MS--clinical features and pathophysiology. Nat Rev Neurol (2013) 0.89
No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis. Arch Neurol (2011) 0.89
Doxorubicin release triggered by alginate embedded magnetic nanoheaters: a combined therapy. Adv Mater (2010) 0.89
New-onset atrial fibrillation in severe sepsis and risk of stroke and death: a critically appraised topic. Neurologist (2012) 0.89
Role of endoscopic ultrasound during hospitalization for acute pancreatitis. World J Gastroenterol (2010) 0.89
Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol (2011) 0.88
Predictors of increased radiation dose during percutaneous coronary intervention. Am J Cardiol (2009) 0.88
Smoking in prisons: the need for effective and acceptable interventions. J Public Health Policy (2010) 0.88
"Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases. Neurologist (2007) 0.86
Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist (2007) 0.86
Health services for prisoners. BMJ (2011) 0.86
Substance abuse treatment clinician opinions and infectious disease service delivery. J Addict Dis (2009) 0.86
Complete remission of gastric Burkitt's lymphoma after eradication of Helicobacter pylori. World J Gastroenterol (2009) 0.85
OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol (2006) 0.85
The other half of Hebb: K+ channels and the regulation of neuronal excitability in the hippocampus. Mol Neurobiol (2002) 0.85
Does cervical manipulative therapy cause vertebral artery dissection and stroke? Neurologist (2008) 0.85
Palliative Care Version 1.2016. J Natl Compr Canc Netw (2016) 0.85
Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist (2011) 0.85
Retrograde intramedullary nailing of femoral diaphyseal fractures caused by low-velocity gunshots. Orthopedics (2009) 0.84
Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn) (2010) 0.84
Serum neuron specific enolase to predict neurological outcome after cardiopulmonary resuscitation: a critically appraised topic. Neurologist (2009) 0.84
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. Neurologist (2008) 0.84
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Neurologist (2012) 0.83
Temporal differences in blood meal detection from the midguts of Triatoma infestans. Rev Inst Med Trop Sao Paulo (2012) 0.83
A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol (2011) 0.83